CTOs on the Move

Beth Israel Deaconess Hospital-Plymouth

www.bidplymouth.org

 
In January 2014, Jordan Hospital joined the Beth Israel Deaconess Medical Center family of hospitals and become Beth Israel Deaconess Hospital-Plymouth. In 1899, a group of leading citizens from Plymouth saw a need to build a hospital to serve residents and pursued the idea of "a hospital on the hill". They approached retail tycon, philanthropist, and summer resident Eben Jordan, of the Jordan Marsh Company, and he donated $20,000 to build was was to become Jordan Hospital. In December 1903, Jordan Hospital opened its doors to the first patients and has remained a community hospital ever since. In 2014, Jordan Hospital ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

PAT Services

PAT Services is a Cleveland, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

PMG of Santa Cruz

PMG of Santa Cruz is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Santa Cruz, CA. To find more information about PMG of Santa Cruz, please visit www.pmgscc.com

Salient Surgical Technologies

Salient Surgical Technologies, Inc. is a Portsmouth, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Fungal Free Nails

Fungal Free Nails is a Encino, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Alector

Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel therapeutics for Alzheimer`s disease, other forms of dementia, and mechanistically related neurodegenerative disorders. Alector`s strategy is to efficiently generate and validate antibody drugs with unique functional properties that engage key disease-altering targets. This approach is enabled by a strategic alliance with Adimab, the industry leader in discovery and optimization of antibody therapeutics. Alector is currently developing leads for 4 major targets and anticipates taking 2 of these through pre-clinical development and IND enabling studies within 24 months. Alector has incorporated a highly integrated and lean biotechnology structure with extensive outsourcing that supports core scientific and management teams.